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the instruments’ Total Symptom Scores (TSS; item-scale correlations0.40). Inter-
nal consistency was strong (D-ABS TSS 0.92; D-MIQ Worries of Hypoglycemia
0.70; WN 0.90). Test-retest reliability was acceptable for both instruments
(D-ABS TSS ICC0.66; D-MIQ Worries of Hypoglycemia ICC0.65 WN ICC0.92).
CONCLUSIONS: The D-ABS and D-MIQ are psychometrically valid surveys for the
assessment of symptoms and impacts for T2DM. The surveys developed in this
study reduce the time required for the assessment of HS frequency and severity
(D-ABS), MC and MT, and weight impact (D-MIQ) in T2DM patients. The combina-
tion of psychometric validity and assessment time reduction make the D-ABS and
D-MIQ a viable means for in-trial and clinical assessment of HS and impacts.
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OBJECTIVES: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a novel class
of drugs to treat patients with Type 2 Diabetes Mellitus (T2DM). The attributes of
the SGLT2i differ from those of other medications. Therefore, patients’ preferences
for each of these attributes are of potential interest to patients, physicians, and
payers.METHODS:A discrete choice experiment was conducted with patients with
T2DM from the UK to examine 7 attributes of T2DM medications: efficacy (defined
as reduction in blood glucose levels), urinary tract infection/genital infection side-
effects, weight change, gastrointestinal/nausea side-effects, hypoglycemic events,
blood pressure, and cardiovascular risk. Patients were presented with 20 total
choices between 2 hypothetical T2DM medications each described by varying lev-
els of the 7 attributes. Partial utilities were estimated using random effects multi-
logit models, and relative importance (RI) values were calculated for each of the
attributes. Data were analyzed for the overall sample, and by medication and gen-
der subgroups. RESULTS: One hundred patients with T2DM completed the study
(51% male; mean age62.9, SD11.1 years; mean BMI32.7, SD6.5; 50.0% taking
2T2DM medications). The four most important attributes to patients were: risk of
hypoglycaemic events (relative importance (RI) 24.7%), weight change associated
with the medication (RI20.6%), risk of gastrointestinal/nausea side-effects
(RI18.6%), and efficacy (RI18.0%). The remaining attributes were of lesser impor-
tance: risk of urinary tract infection/genital infection side-effects (RI9.9%), car-
diovascular risk (RI4.3%), and blood pressure changes (RI3.9%). Additional re-
sults for subgroup analyses will be presented. CONCLUSIONS: Patients with T2DM
consider the risk of hypoglycaemic events, weight changes associated with a med-
ication, the risk of gastrointestinal/nausea side-effects, and the efficacy of a med-
ication to be attributes of approximately equivalent importance for T2DM medica-
tions. Prescribing physicians should consider these characteristics of medications
as they may contribute to patients’ overall satisfaction with their diabetes therapy.
PDB58
THE PSYCHOMETRIC PERFORMANCE OF THE EQ-5D, SF-6D AND DIABETES
HEALTH PROFILE (DHP-18) IN TYPE 2 DIABETES
Mulhern B1, Churchman D2, Meadows K3
1University of Sheffield, Sheffield, UK, 2University of Oxford, Oxford, UK, 3DHP Research &
Consultancy Ltd, Banbury, UK
OBJECTIVES: Generic preference-based measures such as EQ-5D and SF-6D and
condition specific measures such as the Diabetes Health Profile-18 (DHP-18) are
used in the assessment of health related quality of life in diabetes. The aim of this
study was to investigate the psychometric acceptability, validity and responsive-
ness of these measures in a type 2 diabetes population. METHODS: Acceptability
was assessed by calculating missing data rates. We investigated the convergent
validity of the measures using correlations, known group validity across a variety
of clinical indicators using ANOVA, and agreement between the measures using
Intra Class Correlation coefficients (ICC) and Bland Altman plots. Responsiveness
to change over time was assessed using standardised response mean, and floor/
ceiling effect tests. A UK longitudinal sample of 1613 people with Type 2 diabetes
was used for the analysis.RESULTS:Overall rates of missing data were less than 5%
indicating acceptability to respondents. Across both time points, the DHP-18 di-
mensions were moderately correlated with the EQ-5D and SF-6D indicating con-
struct validity. All three measures significantly discriminated between those re-
porting and not reporting co-morbid health problems. In terms of agreement, the
ICC between the preference based measures was high, and Bland Altman plots
indicated that agreement is higher at the less severe end of the scale. The EQ-5D
displays evidence of a ceiling effect, and for patients self reporting change in
health, SRM statistics indicate that the sensitivity to change across time is low for
all measures.CONCLUSIONS:There is evidence for the psychometric validity of the
generic preference based measures EQ-5D and SF-6D and the condition specific
DHP-18 to measure outcomes in diabetes. However evidence for the responsive-
ness of the measures is less clear. The inclusion of both generic and condition
specific measures in trials may increase the accuracy of outcomes assessment in
type 2 diabetes.
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OBJECTIVES: Intensive glycemic control can increase the risk of hypoglycemia
among type 2 diabetes (T2D) patients, especially for people treated with insulin or
sulfonylureas. The goal of this study was to establish the content validity of a new
patient-reported outcome (PRO) instrument assessing multiple dimensions of the
patient’s experience of hypoglycemia – the Hypoglycemia Perspectives Question-
naire (HPQ). METHODS: The study included concept evaluation (to identify key
hypoglycemia perspectives to be assessed in the instrument), item generation, and
cognitive interviewing (to assess patient understanding of the HPQ) phases. The
concept evaluation phase included interviews with 19 T2D patients (mean age 
54.4, 37% male, 74% Caucasian) and 4 key opinion leaders, and a targeted review of
the literature. Two phases of cognitive interviews were conducted with T2D pa-
tients (Phase I: n6; Phase II: n5; 55% male, 45%  50 years old, 82% Caucasian);
changes to the HPQ were made in between phases. In concept elicitation and
cognitive interviews, respondents were interviewed one-on-one by a trained mod-
erator using a semi-structured interview guide. RESULTS: Key concepts emerging
from the concept evaluation phase included: frequency and severity of events,
emotional response to a hypoglycemia event, symptom concern, importance of
compensatory behaviors, personal control, worries, functional impact, and aware-
ness of symptoms. Tremor (79% of patients), dizziness (68%), and sweating (63%)
were the most commonly reported symptoms. Items were generated to assess the
key dimensions of hypoglycemia. The HPQ instructions, items, and response op-
tions were generally understood and only minor changes were made to the
instrument. CONCLUSIONS: The HPQ is a PRO instrument that can be used in
studies of T2D patients. It provides a comprehensive assessment of the patient’s
perspectives on hypoglycemia that goes beyond existing instruments. Once the
items are finalized via psychometric testing, the HPQ may be used to evaluate the
burden of hypoglycemia.
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OBJECTIVES: Fear for hypoglycemia has an impact on type 2 diabetes mellitus
(T2DM) patients’ Health-Related Quality of Life (HRQoL). The Worry Subscale of the
Hypoglycaemic Fear Survey-II (HFS-II) is a widely used tool. The objective is to test
the internal consistency, validity and reliability of a Spanish version of HFS-II for
determining the impact of fear for hypoglycemia on T2DM patients’ HRQL in Spain.
METHODS: Observational, cross-sectional, multicentre design. T2DM patients di-
agnosed from at least 1 year were recruited consecutively. Use of research tools:
1)Audit of Diabetes-Dependent Quality of Life/ADDQoL questionnaire [-9 to 9,
more negative scores indicate greater negative impact of diabetes on QoL];2)Worry
subscale of HFS-II [0-72, higher scores indicate increased fear];3)Visual Analogue
Scales (VAS) [0-10, higher scores indicate greater fear and impact of hypoglycemia].
For determining HSF-II internal consistency, validity and reliability, next parame-
ters were calculated: Cronbach’s alpha; ceiling/floor effects; correlations between
similar items scores of HFS-II/ADDQoL and between scores of two anchor ques-
tions (VAS) /HFS-II. RESULTS: A total of 3,812 patients (661 health care centers)
participated in the study [men (53.57%);mean(SD) age 63.70(11.37) years;mean(SD)
time from T2DM diagnosis 9.67(6.91) years]. 44.88% of patients referred at least one
episode of hypoglycemia in the previous six months. Mean(SD) HFS-II subscale
score was 24.41(17.05). It was higher in patients with hypoglycemia [31.32(15.71)]
compared to those without [18.85(16.03)](p0.0001). Cronbach’s alpha was 0.964. A
negative correlation was found between ADDQoL and HFS-II mean scores (-0.441;
p0.0001). Items that explore physical capacity, family, confidence, motivation,
future and dependence in ADDQoL and in HFS-II showed the highest correlations.
Anchorage questions’ (VAS) correlations (0.522-0.597) demonstrated an acceptable
face validity of the HFS-II individual items. Ceiling/floor effects below 20% suggest
its good functionality. CONCLUSIONS: These preliminary results show that the
HFS-II is consistent, valid and reliable for assessing fear for hypoglycemia in T2DM
patients in Spain.
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OBJECTIVES: To know the incidence and cost of hypoglycemia episode in patients
with type 2 diabetes mellitus (T2DM) in China METHODS: A face-to face interview
was performed in 2 hospitals in Beijing and Tianjin with a well designed question-
naire. The incidence of mild, moderate and severe hypoglycemia as well as the
daily prevention cost and management cost per event were collected and investi-
gated in this study. RESULTS: The overall incidence of the study population was
54.04% within 1 year. A total 146 mild hypoglycemia episodes were reported in 79
patients within 1 week. A total 54 moderate hypoglycemia episodes were reported
in 37 patients within 1 month. A total 6 severe hypoglycemia episodes were re-
ported in 6 patients within 1 year. The well controlled (Fast Blood Glucose )FBG
group experienced the most mild hypoglycemia episodes and the group with treat-
ment of oral hypoglycemic agents combined with insulin had the highest hypogly-
cemia incidence within 1 year. The mean costs for mild, moderate and severe
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